An antiviral coating technology developed by the University of Manchester, alongside Virustatic, has numerous product applications. The first product being developed for Sterling Materials is an antiviral facemask, which will provide the only protection to an influenza pandemic and will be vital in saving millions of lives.
The Manchester research team, led by Professor Sabine Flitsch, identified a coating to mimic the surface of the cells in the human oesophagus and nasal passages. The method can capture over 99% of all flu viruses, including new strains of pandemic flu that come into contact with it. Virustatic and the University are leading the prototype testing for the impregnated fabric for Sterling Materials.
Paul Hope, Virustatic’s Technical Director and Inventor, is confident that the combination of research excellence and business acumen will move the technology into mainstream use.
“Great ideas have a habit of becoming bad – or even non-existent – products. The ability to commercialise research is very difficult and the expense often outweighs benefits. Put simply, many commercial products using research breakthroughs are just too expensive to sell.
“Virustatic will really motor through this barrier as we have perfected a method of using inexpensive substrates to carry our technology so Sterling Materials will get access to extremely essential , life-saving technology which has minimal impact on production costs.”